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Background: Mortality from cardiovascular disease in the Middle East is projected to increase substantially
in the coming decades. The prevalence of metabolic syndrome (MS) in acute coronary syndrome (ACS)
continues to raise interest, but data from the Middle East is limited, especially in non-diabetic patients. This
study was conducted to ascertain the prevalence of MS and frequency of its components, individually and
in combination, in a male population presenting with ACS, but without a previous diagnosis of diabetes
mellitus (DM).
Methods: This is a prospective study of 467 consecutive male patients hospitalized for ACS. They were
categorized according to the specific criteria stated in the latest joint statement for the global definition
of MS.
Results: The mean age was (49.7910.7 years). Of the 467 patients, 324 (69.4%) fulfilled the criteria for MS.
ST-Elevation Myocardial Infarction (STEMI) was identified in 178 patients (54.9%), and non-ST elevation
ACS (NSTE-ACS) in 146 patients (45.1%). These proportions were not significantly different from those
without MS (STEMI 51.7% vs. NSTE-ACS 48.3%, respectively). However, patients with MS were older
(50.6910 vs. 47.9911 years; p0.012), and more than half of those with MS were above 50 years. The most
common abnormal metabolic components were reduced high-density lipoprotein cholesterol (HDL-c; 94.1%),
elevated fasting blood glucose (FBG; 89.8%), and elevated triglycerides (81.8%), followed by increased waist
circumference (61.7%) and raised blood pressure (40.4%). The majority of patients with MS had three or
more metabolic components (326 patients, 69.4%), and 102 (21.8%) had two components, but only 37 (8.4%)
had a single component.
Conclusions: In ACS patients, without previous history of DM, MS is highly prevalent. Reduced HDL,
elevated FBG and triglycerides were the most frequent metabolic components. The majority had multiple
components. These findings raise alarm and show that drug therapy alone may not be fully effective, unless
the underlying risk factors causing MS, such as weight and exercise, are also tackled.
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M
etabolic syndrome (MS) is a cluster of risk
factors thought to contribute to the pathogen-
esis of atherosclerosis. The reported prevalence
of MS among patients with acute coronary syndrome
(ACS) varies between 29 and 62% (17). There is only
limited data about the prevalence of MS in patients with
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ACS, particularly in the Middle-East populations.
Furthermore, most studies have mixed diabetic and
non-diabetic populations. In fact, they often have pre-
dominantly diabetic patients.
This prospective study was designed to focus on the
prevalence of MS in patients admitted with ACS, but
without a history of diabetes mellitus (DM), a population
that has received less attention than those with DM.
We also decided to concentrate on male subjects,
as the majority of females admitted with ACS have
DM. Furthermore, some of the components of MS are
different for male and female subjects.
The criteria of MS were surrounded by differences
among world authorities. In an attempt to eliminate
some of the confusion, the latest joint statement was
developed by a conglomerate of international organiza-
tions, including the International Diabetes Federation
(IDF), the National Heart, Lung and Blood Institute
(NHLBI), the World Heart Federation, the International
Atherosclerosis Society, and the American Heart Asso-
ciation (AHA). These organizations have agreed on
specific criteria for the global diagnosis of MS. This
definition places major emphasis on central obesity in
this condition. The criteria adopted for increased waist
circumference are based on population and country spe-
cific definitions (8). Therefore, we sought to apply these
criteria on a prospective hospital-based study of male
patients in a Middle Eastern country who had ACS.
The present study aims to ascertain the prevalence of
MS and the frequency of its components individually
and in combinations, in this specific male population.
Methods
Study design and population
In this prospective hospital-based study, we enrolled a
total of 467 consecutive male patients who attended the
emergency department and who were admitted to the
Coronary Care Units, Hamad Medical Corporation,
Doha, Qatar, with the diagnosis of ACS. Qatar has a
population of around 1,720,000 according to the 2011
Qatar Statistics Authority (9).
The study was approved by the review board of
the research committee in our institution prior to patient
enrolment. Each participant was provided with full
information about the study and was assured of strict
confidentiality. Only participants who consented to
participate were included in the study. Standard defini-
tions were used to diagnose ACS in patients who had
acute myocardial infarction (MI) (10) or unstable angina
(11). Those who had acute MI were defined by a posi-
tive serial troponin-T blood test result (]0.1 ng/mL)
in the setting of symptoms and electrocardiographic
changes consistent with either ST-elevation MI (STEMI)
or non ST-elevation MI (NSTEMI). Unstable angina was
diagnosed if the patient had a negative troponin blood
test, but had any one of the following characteristics:
new-onset angina (B2 months) of at least class III
according to the Canadian Cardiovascular Society,
prolonged (20 min) angina at rest, recent (B2 months)
worsening of angina pectoris, or angina that occurred
within 2 weeks of an acute MI (11). All patients who were
labeled with unstable angina but later found to have an
alternative diagnosis were excluded. Each participant was
prospectively interviewed during their first day of admis-
sion to ascertain lack of history of DM. Patients’ medical
records and medications were also scrutinized for evi-
dence of a previous diagnosis of DM. Only patients
who lacked evidence of DM were deemed eligible to
participate in the study.
Anthropometric measurements were obtained during
admission for all patients. Height was measured in
centimeters while the subject was standing in bare feet
and with normal straight posture. Weight was measured
in kilograms first thing in the morning before breakfast
and body mass index (BMI) was calculated. Waist
circumference was measured in centimeters atop the iliac
crests before breakfast. Blood pressure was an average
of at least two values automatically taken in the right
upper arm during 1 h on first day of admission.
In the present study, we adopted the latest joint
statement for the definition of MS, which identifies the
global criteria based on population and country specific
definitions for elevated waist circumference (Appendix 1,
2) (8, 12, 13).
A single set of cutoff points were used for all compo-
nents except waist circumference. National or regional
cutoff points for waist circumference were used. Male
patients were diagnosed as having MS if they had any
three of the following five components:
1) abdominal obesity (waist circumference 94 cm for
Middle East and Mediterranean or 90 cm for
Asians);
2) elevated triglyceride levels ]1.7 mmol/L (150 mg/
dL) or on drug treatment for hypertriglyceridemia;
3) reduced high-density lipoprotein-cholesterol (HDL-
c) levels B1.0 mmol/L (40 mg/dL) or on drug
treatment for low HDL-c;
4) repeated readings of elevated blood pressure (sys-
tolic ]130 and/or diastolic ]85 mm Hg) taken
under standard conditions, or on active treatment
for hypertension;
5) elevated fasting glucose levels ]5.6 mmol/L (100
mg/dL).
Three sets of serial blood samples were obtained by
vein puncture from all patients for cardiac biomarkers,
including troponin-T and creatine kinase-MB. Blood was
also drawn after a minimum of 12 h of fasting to measure
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triglycerides, HDL-c, and FBG. All biochemical para-
meters were assayed on Vitalab Selectra-EClinical
Chemistry Analyzer.
Although the primary aim of this study was to describe
the prevalence of various MS components among male
patients who presented with ACS without a previous
diagnosis of DM, secondary analyses were also per-
formed for the socio-demographic and clinical character-
istics, such as age, BMI, smoking, type of ACS, and
the findings were compared between patients with and
without MS.
Statistical methods
Data were analyzed by using the Statistical Package for
Social Sciences (SPSS, version 15.0). Both descriptive and
analytic statistics were used in the data analysis. For
categorical variables, basic descriptive statistics are re-
ported as numbers and percentages.
Differences in the distribution of selected character-
istics between groups with MS or without MS were
examined by using chi-square tests of statistical signifi-
cance for categorical variables. A two-tailed paired t-test
was used to compare normal continuous variables.
Fisher’s exact test was used to compare discrete measures
and proportions. A p-value of less than 0.05 was con-
sidered statistically significant. For the purpose of easier
analysis, non-ST elevation MI (NSTEMI) and unstable
angina (UA) were grouped together in a common group
and labeled NSTE Acute Coronary Syndrome (NSTE-
ACS), as opposed to ST-elevation MI (STEMI). This has
been used by several recent studies (14, 15).
Results
The study population consisted of 467 men admitted
with ACS. The mean age (9SD) was 49.7910.7 years.
A total of 324 (69.37%) patients fulfilled the criteria
stated in the latest joint statement for the definition of
MS (8). Among them, STEMI was present in 178 (54.9%)
patients and NSTE-ACS in 146 (45.1%) patients (p-value,
non-significant).
Table 1 shows the distribution of patients according to
their socio-demographics and clinical characteristics.
ACS patients with MS were older than patients without
MS (50.6910 vs. 47.9911; p0.012). More than half
of the patients with MS were older than 50 years,
as compared to those without MS (53.7% vs. 46.9%,
pB0.001). On the contrary, younger patients with MS
(B40 years) made up a significantly less proportion than
those without MS (12% vs. 27.3%, pB0.001).
Patients with MS had a higher prevalence of increased
BMI as compared to the group without MS (BMI means
27.594.3 vs. 24.993.5; pB0.001). As for obesity (30
kg/m2), the prevalence was 22.8% versus 9.1%, respec-
tively (pB0.001). The overall prevalence of smoking in
our cohort was 37.3% and there was no significant
difference in the prevalence of current smokers between
those with and without MS: 122 (37.7%) versus 52
(36.4%), respectively (p0.836). There was also no
significant difference in the prevalence of different types
of ACS between the MS and non-MS groups (STEMI,
54.9% vs. 51.7%; NSTE-ACS, 45.1% vs. 48.3%, respec-
tively; p0.294 for both).
The prevalence of each of the metabolic components
among patients with or without MS is shown in Fig. 1.
The reduced HDL-c observed in 305 patients (94.1%)
and the elevated fasting blood glucose (FBG) in 291
patients (89.8%) were the most common metabolic
components. The next most frequent components were
increased waist circumference in 265 patients (81.8%),
elevated triglyceride in 200 patients (61.7%) and raised
blood pressure in 131 patients (40.4%). The mean value
of HDL-c was significantly lower in MS than in non-MS
patients (0.990.3 vs. 1.190.3; pB0.001). While trigly-
cerides mean value was significantly higher in MS than
in non-MS patients (2.291.4 vs. 1.290.5; pB0.001),
the mean value for FBG was significantly higher in the
MS than in the non-MS group (7.292.5 vs. 6.392.7;
pB0.001). The mean systolic and diastolic blood pressure
values were slightly but significantly higher in patients
with MS than in those without MS (systolic, 119.1919.7
vs. 113.3914.8, respectively; diastolic, 70.2913.6 vs.
66.299.2, respectively; p0.002 for both).
In patients with ACS, the majority (324 patients,
69.4%) had three or more (35) components. Less than
one-third (143 patients, 30.6%) had two or fewer compo-
nents of MS (Fig. 2). Only 39 patients (8.4%) had a single
component of MS.
Discussion
MS consists of a cluster of metabolic disorders, many
of which promote the development of atherosclerosis
and increase the risk of cardiovascular diseases. Western
studies suggest that MS is very commonly associated with
coronary artery disease (2). However, there is very limited
information about the prevalence of MS in ACS patients
in the developing world, particularly in the Middle East.
To the best of our knowledge, this is the first prospec-
tive study from the Middle East region to address the
prevalence of MS in patients presenting with ACS
without a previous diagnosis of DM.
Because of the previous diversity in the definition of
MS criteria, the reported prevalence of MS in patients
with ACS ranges between 29 and 34% when known
diabetics where excluded (1, 4), and between 38 and
62% in studies where diabetic patients were included (2, 3,
57). Analyzing some of the studies that evaluated the
prevalence of MS in ACS before the latest joint defini-
tion of MS reveals interesting discrepancies. In a study
using the criteria of the National Cholesterol Education
Program-Adult Treatment Panel III (NCEP ATP-III),
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the prevalence of MS was 46% in a cohort of 633 patients
with STEMI (2). Milani et al. assessed 235 consecutive
patients after a coronary event and reported a prevalence
of 62% (6), while a Canadian study reported a prevalence
of MS in up to 51% (16).
In the present study, we show that the prevalence
of MS in male patients hospitalized with ACS was
69.37%, when MS is defined according to the latest
joint statement criteria. This is considerably higher than
some other studies, especially bearing in mind that our
patients did not have a history of diabetes. This could
be attributed to several factors. First, the reported
prevalence rate of MS in the general population of
35.4% (using the IDF definition of MS), which is
considerably higher in Qatar than that reported in
nearby Gulf and Western countries (17). Second, the
cutoff of waist circumference of the latest global
definition that we applied is lower than that used by
previous reports adopting the criteria of the NCEP/ATP
III in 2001 (12), or the criteria of the AHA/NHLBI in
Table 1. Socio-demographics and clinical characteristics of 467 male patients with (324 patients) or without (143 patients)
metabolic syndrome
ACS patients
Variable Total, n (%)
Patients with
metabolic syndrome, n (%)
Patients without
metabolic syndrome, n (%) p
Number of patients 467 (100) 324 (69.3) 143 (30.6)
Age in years (mean9SD) 49.7910.7 50.6910.2 47.9911.8 0.012
Age group in years
B40 78 (16.7) 39 (12.0) 39 (27.3)
B0.001
4049 148 (31.7) 111 (34.3) 37 (25.9)
5059 182 (39) 133 (41) 49 (34.3)
]60 59 (12.6) 41 (12.7) 18 (12.6)
BMI, kg/m2 (mean9SD) 26.794.3 27.594.3 24.993.5 B0.001
Patients according to BMI
Normal (B25 kg/m2) 175 (37.5) 90 (27.8) 85 (59.4)
B0.001Overweight (2530 kg/m2) 205 (43.9) 160 (49.4) 45 (31.5)
Obese (30 kg/m2) 87 (18.6) 74 (22.8) 13 (9.1)
Current smokers 174 (37.3) 122 (37.7) 52 (36.4) 0.836
Blood pressure (mm Hg)
Systolic (mean9SD) 117.4918.6 119.1919.7 113.3914.8 0.002
Diastolic (mean9SD) 69.0912.6 70.2913.6 66.299.2 0.002
Waist circumference cm (mean9SD) 95.0911.5 97.8910.3 88.4911.5 B0.001
Lipid profile mmol/L
Total cholesterol 4.891.3 4.991.3 4.691.3 0.014
High density lipoprotein (mean9SD) 1.090.3 0.990.3 1.190.3 B0.001
Low density lipoprotein (mean9SD) 3.191.3 3.191.3 2.991.2 0.071
Triglycerides (mean9SD) 1.991.3 2.291.4 1.290.5 B0.001
Fasting blood sugar mmol/L (mean9SD) 7.092.6 7.292.5 6.392.7 B0.001
Acute coronary syndrome
STEMI 252 (54) 178 (54.9) 74 (51.7)
0.294
NSTE-ACS 215 (46V) 146 (45.1) 69 (48.3)
Metabolic syndrome components
Elevated waist circumference 303 (64.9) 265 (81.8) 38 (26.6) B0.001
Elevated triglycerides 216 (46.3) 200 (61.7) 16 (11.2) B0.001
Reduced HDL cholesterol 407 (87.2) 305 (94.1) 102 (71.3) B0.001
Elevated blood pressure 150 (32.1) 131 (40.4) 19 (13.3) B0.001
Elevated fasting glucose 359 (76.9) 291 (89.8) 68 (47.6) B0.001
Data are expressed as number (%) of patients unless otherwise indicated.
ACS: acute coronary syndrome, BMI: body mass index, STEMI: ST-elevation myocardial infarction, NSTE-ACS: non-ST elevation-acute
coronary syndrome, HDL-c: high-density lipoprotein cholesterol.
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2005 (18), which applied a waist circumference of ]102
cm in men. These factors may, in part, explain the
higher prevalence of MS in the present study.
There was no significant difference in the prevalence
of different types of ACS between groups with and
without MS. Among the 467 patients studied, 54% had
STEMI and 46% had NSTE-ACS. With regard to age,
it is worth noting that MS prevalence peaked at 53.7%
in persons older than 50. A similarly high prevalence of
the MS in AMI patients (46%) among older age groups
was also reported by Zeller et al. (2). In contrast to the
older age group (50 years), the prevalence of MS
among the younger age group (B40 years) showed
a significant lower proportion with than without MS
(12% vs. 27.3%, respectively; pB0.001). This may point
to other overriding covariates like dyslipidemia or sub-
clinical inflammation, which might play a stronger role
in younger patients. This mandates further investigation.
Obesity and being overweight were significantly more
prevalent in the MS group, a finding similar to results
reported from neighboring countries on populations
even without ACS (19, 20).
The majority of our patients had three or more
components (69.4%). Less than one-third (30.6%) had
two or fewer components of MS. This indicates that
not only is MS prevalent, but if severity could be
implied by the number of components, most patients
had a severe form also. Among the individual compo-
nents of MS, we found reduced HDL-c to be the most
common component (87.2%), followed by elevated FBG
(76.9%). Most patients had not had an encounter
with physicians before, and for many the admission
with ACS was the first such encounter. Therefore,
almost all patients did not have a glucose tolerance
test or HbA1c measurement before this admission.
This underscores the importance of public screening
programs, especially in communities with high preva-
lence of DM.
The overall findings of the study underscore the need
for lifestyle modification, particularly in view of the
living environment in some Middle Eastern countries,
which is witnessing fast economic development and
urbanization, in addition to a hot climate which might
discourage outdoor activities and instead encourage a
sedentary life. It is worth emphasizing that while some
components of MS can be treated by medication, there
are components that are much easier and more effectively
controlled by improved diet and exercise. Hence, national
and regional health and nutrition education programs
of the population are needed, and the role of health
institutions in this regard is critical.
Conclusion
MS has become a global and major public health
problem. The present study reveals a high prevalence of
MS (67.92%) in male patients with ACS but without a
previous diagnosis of DM. The majority had three or
more components of MS. Reduced HDL-c was the most
common metabolic abnormality While there is often
emphasis on drug therapy to treat MS, our findings
suggest that this may not be adequate, unless other
important measures, like diet and physical activity, are
also emphasized in population campaigns.
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Fig. 1. Prevalence of metabolic components in male
patients presenting with acute coronary syndrome with or
without metabolic syndrome. Data are expressed in percen-
tage of patients. ACS: acute coronary syndrome, MS:
metabolic syndrome, non-MS: non-metabolic syndrome,
WC: elevated waist circumference, TG: elevated triglyceride,
HDL-c: reduced high-density lipoprotein-cholesterol, BP:
elevated blood pressure, FPG: elevated fasting plasma
glucose levels.
Fig. 2. Individual metabolic abnormalities among a male
population with acute coronary syndrome (N467). Data
are expressed as number (%) of patients. ACS: acute
coronary syndrome.
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Appendix 2. Current recommended waist circumference thresholds for abdominal obesity by organization (8)
Recommended waist circumference threshold applied for abdominal obesity
Population Organization (Reference) Men (cm) Women (cm)
Asian (including Japanese) IDF (12) ]90 ]80
Asian WHO (13) ]90 ]80
Middle East, Mediterranean IDF (12) ]94 ]80
IDF: International Diabetes Federation, WHO: World Health Organization.
Appendix 1. Criteria for clinical diagnosis of the metabolic syndrome (8) applied to the 467 male patients studied
Measure Categorical cutoff points
Elevated waist circumference* Population- and country-specific definitions
Elevated triglycerides (drug treatment for elevated triglycerides is an
alternate indicator$)
]150 mg/dL (1.7 mmol/L)
Reduced HDL-c (drug treatment for reduced HDL-c is an alternate
indicator$)
B40 mg/dL (1.0 mmol/L) in males; B50 mg/dL (1.3 mmol/L) in
females
Elevated blood pressure (antihypertensive drug treatment in a patient
with a history of hypertension is an alternate indicator)
Systolic ]130 and/or diastolic ]85 mm Hg
Elevated fasting glucose% (drug treatment of elevated glucose is an
alternate indicator)
]100 mg/dL
HDL-c: high-density lipoprotein cholesterol.
*It is recommended that the IDF cut points be used for non-Europeans and either the IDF or AHA/NHLBI cut points used for people of
European origin until more data are available.
$The most commonly used drugs for elevated triglycerides and reduced HDL-c are fibrates and nicotinic acid. A patient taking one of
these drugs can be presumed to have high triglycerides and low HDL-c. High-dose omega-3-fatty acids presume high triglycerides.
%Most patients with type 2 diabetes mellitus will have metabolic syndrome according to the proposed criteria.
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